WG
CTMX icon

Winton Group’s CytomX Therapeutics CTMX Stock Holding History

Winton Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,100
Closed -$146K – 1240
2026
Q1 		$146K Buy
+31,100
New +$158K 0.01% 1013
2019
Q2 		– Sell
-10,541
Closed -$113K – 1153
2019
Q1 		$113K Buy
+10,541
New +$156K ﹤0.01% 1024
2018
Q2 		– Sell
-7,214
Closed -$205K – 1041
2018
Q1 		$205K Buy
+7,214
New +$206K 0.01% 1100

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Winton Group's CTMX Position: Q2 2026 in Review

Winton Group sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 31,100 shares — an estimated $146K sold.

Winton Group first reported a position in CTMX in Q1 2018 and held it in 3 quarters. The position peaked at $205K in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Winton Group reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 31,100 CytomX Therapeutics shares in Q2 2026, an estimated $146K.
  • Winton Group first reported a position in CytomX Therapeutics in Q1 2018 and held it in 3 quarters.
  • Winton Group's CytomX Therapeutics position peaked at $205K in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.